Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S. 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
Vietnam’s EV Taxi Giant GSM Eyes Hong Kong IPO With $2–3 Billion Valuation 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
Winter Storm Disrupts Northeast Travel as Snow and Ice Blanket New York, New Jersey 
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
NEW YORK, Feb. 27, 2017 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of New York on behalf of investors who purchased Aratana Therapeutics, Inc. (NASDAQ:PETX) securities between March 16, 2015 and February 3, 2017.
Click here to learn about the case: http://www.wongesq.com/pslra/aratana-therapeutics. There is no cost or obligation to you.
According to the complaint, throughout the Class Period Defendants made false and/or misleading statements and/or failed to disclose that: (1) Aratana did not have manufacturing contracts in place sufficient to support manufacturing of ENTYCE at a commercial scale; (2) therefore, ENTYCE was not likely to be commercially available until late 2017; (3) accordingly, Aratana had misled investors regarding the probable timeline for a commercial launch of ENTYCE; and (4) consequently, Aratana’s public statements were materially false and misleading at all relevant times.
If you suffered a loss in Aratana you have until April 7, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/aratana-therapeutics.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
